Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Virology
|
December 23, 2008
Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies
Scott Parker, Akbar M Siddiqui, Christina Oberle, et al.
Antiviral Research
|
October 2, 2007
Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model
Scott Parker, Erin Touchette, Christina Oberle, et al.
Viruses
|
April 19, 2011
Development of CMX001 for the Treatment of Poxvirus Infections
Randall Lanier, Lawrence Trost, Tim Tippin, et al.
Antiviral Research
|
August 17, 2014
Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus
Scott Parker, Ryan Crump, Scott Foster, et al.
Antiviral Research
|
March 3, 2012
Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox
Scott Parker, Nanhai G Chen, Scott Foster, et al.
Clinical and Translational Science
|
March 26, 2025
Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19
Akshita Chawla, Ruthie Birger, Brian M Maas, et al.
Science Translational Medicine
|
April 18, 2014
An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model
Stefanie A Krumm, Dan Yan, Elise S Hovingh, et al.
Viruses
|
March 5, 2011
Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans
Amanda D Rice, Mathew M Adams, Greg Wallace, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
October 6, 2023
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals
Sébastien Bihorel, Youfang Cao, Akshita Chawla, et al.
Nature
|
February 9, 2021
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl, Lisa E Gralinski, Claire E Johnson, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Virology
|
December 23, 2008
Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies
Scott Parker, Akbar M Siddiqui, Christina Oberle, et al.
Antiviral Research
|
October 2, 2007
Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model
Scott Parker, Erin Touchette, Christina Oberle, et al.
Viruses
|
April 19, 2011
Development of CMX001 for the Treatment of Poxvirus Infections
Randall Lanier, Lawrence Trost, Tim Tippin, et al.
Antiviral Research
|
August 17, 2014
Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus
Scott Parker, Ryan Crump, Scott Foster, et al.
Antiviral Research
|
March 3, 2012
Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox
Scott Parker, Nanhai G Chen, Scott Foster, et al.
Clinical and Translational Science
|
March 26, 2025
Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19
Akshita Chawla, Ruthie Birger, Brian M Maas, et al.
Science Translational Medicine
|
April 18, 2014
An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model
Stefanie A Krumm, Dan Yan, Elise S Hovingh, et al.
Viruses
|
March 5, 2011
Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans
Amanda D Rice, Mathew M Adams, Greg Wallace, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
October 6, 2023
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals
Sébastien Bihorel, Youfang Cao, Akshita Chawla, et al.
Nature
|
February 9, 2021
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
Angela Wahl, Lisa E Gralinski, Claire E Johnson, et al.
Page
of 3